About Penta
Who we are
Diversity and Inclusion
Penta ID Network
Penta Foundation Italy
Penta ID Innovation
Annual reports
Our Activities
News & Events
News
Press center
Penta Newsletter
Stories
Scientific Views
Penta Aperitivo Webinars
Publications
Contact us
Work with us
Vacancies
Call for services
Brighter Future Award
Archivio
Zidovudine (ZDV) appears to prevent selection of K65R and L74V, mutations normally selected by Abacavir (ABC) mono- or combination therapies not containing ZDV
Adherence to HAART in children: results from a questionnaire study of children in PENTA 5 trial
96 week follow-up of the PENTA 5 trial; comparing ZDV+3TC, ZDV+ABC and 3TC+ABC with or without NFV in ART naive children
PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection.
Biphasic decay of cell-associated HIV-1 DNA in HIV-1 infected children on antiretroviral therapy
Impact of HIV-1 subtypes on virologic response and emergence of drug resistance
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral naïve HIV-1 infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)
Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial
Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial
Difficulties in achieving suppression of viral replication in vertically HIV-1 infected infants early treated with d4T+ddI+NFV : The PENTA 7 Study.
TREC Response to Antiretroviral Therapy in HIV-infected Children in the PENTA 5 Trial
The Impact of HIV-1 Subtypes on Virological Response and Emergence of Resistance in the PENTA 5 Trial